Mark Stejbach

Mark Stejbach has over 30 years of experience in biotech and pharmaceuticals, including senior roles in a broad range of commercial functions including marketing, sales, economic affairs, managed care, and finance. Mark most recently served as Senior Vice President and Chief Commercial Officer at Alkermes, plc, a publicly traded global biopharmaceutical company, where he was responsible for building sales of Vivitrol from ~$40m to ~$300m.

Prior to his role at Alkermes, Mark served as the Chief Commercial Officer at Tengion, Inc. from 2008 to 2012, and he previously held senior positions at Merck and Biogen. He served as a non-executive director on the board of Flexion Therapeutics (NASDAQ: FLXN), from 2016 until its acquisition in 2021. Flexion marketed a “buy-and-bill” long-acting injectable for the treatment of osteoarthritis. He also previously served as Senior Commercial Advisor to EIP Pharma Inc., a private company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases.

Mark holds an M.B.A. from the Wharton School, University of Pennsylvania, and a B.S. in mathematics from Virginia Tech.